Related Experiment Video
Updated: Aug 19, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Antithrombotic therapy in patients with first-ever stroke and known non-rheumatic atrial fibrillation]
J Gandjour1, J Zeindler, D Georgiadis
1Abteilung für Neuroangiologie, Neurologische Klinik und Poliklinik, Universitätsspital Zürich.
Insights
Patients with atrial fibrillation (AF) often do not receive appropriate stroke prevention therapy. Many high-risk individuals are undertreated, while low-risk patients may be unnecessarily anticoagulated, highlighting a gap in stroke risk management.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Non-rheumatic atrial fibrillation (AF) significantly increases ischemic stroke risk.
- Risk stratification (high, moderate, low) guides antithrombotic therapy choices.
- Current guidelines recommend oral anticoagulants for high-risk AF patients and aspirin for low-risk patients.
Purpose of the Study:
- To evaluate the appropriateness of antithrombotic therapy in patients with first-ever stroke and non-valvular AF.
- To compare actual treatment patterns against recommendations from the Atrial Fibrillation Investigators (AFI) and Stroke Prevention in Atrial Fibrillation (SPAF) studies.
- To identify discrepancies in stroke risk management for AF patients, considering contraindications.
Main Methods:
- Retrospective analysis of prospectively collected data.
- Inclusion of patients with first-ever ischemic stroke and known non-valvular AF.
- Comparison of patient antithrombotic therapy with AFI and SPAF guideline recommendations, accounting for contraindications.
Main Results:
- Only 36% of high-risk AF patients received appropriate therapy per AFI guidelines; 28% per SPAF guidelines.
- Approximately 25% of low-risk AF patients were unnecessarily anticoagulated.
- Significant underutilization of appropriate therapy in high-risk AF patients and overutilization in low-risk patients was observed.
Conclusions:
- Many AF patients with high stroke risk are not receiving recommended antithrombotic therapy.
- A notable proportion of low-risk AF patients are treated with anticoagulants without clear indication.
- There is a critical need to improve adherence to stroke prevention guidelines in atrial fibrillation management.
Abstract:
Patients with non-rheumatic atrial fibrillation (AF) have an increased risk for ischemic stroke. The presence of risk factors such as a history of ischemic stroke, transient ischemic attack, diabetes mellitus, arterial hypertension or advanced age allows the classification of patients with AF in three groups with high, moderate, and low stroke risk. High-risk patients should receive oral anticoagulants, low-risk patients aspirin, and moderate-risk patients one of both antithrombotic agents. However, primary stroke prevention studies suggest that many high-risk patients are not anticoagulated, whereas low risk patients receive anticoagulants instead of aspirin. Our retrospective analysis of prospectively collected data examined the antithrombotic therapy of patients with first-ever stroke and known non-valvular AF and compared the results with the recommendations of the Atrial Fibrillation Investigators (AFI) and the Stroke Prevention in Atrial Fibrillation (SPAF) study. Contraindications against anticoagulation were taken into consideration. High-risk patients received in 36% an appropriate antithrombotic therapy according to the AFI-guidelines, and in 28% according to the SPAF-guidelines. About one quarter of low-risk patients were anticoagulated unnecessarily. Our study confirms that many patients with AF and high stroke risk do not get the appropriate antithrombotic therapy, while some patients with low-risk are anticoagulated without cause.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:27Pulmonary Embolism III: Nursing Management
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...